Did You Know?         

  • Varicose veins are a leading cause of blood clots and chronic leg complaints.
  • Treatment of varicose veins is not “one-size fits all” and treatments need to be individualized.
  • Treatment of varicose veins is generally considered “medically necessary” by the payers.
  • Varithena is a newly FDA approved chemical ablation treatment for refluxing veins contributing to varicose veins and leg edema.
  • Varithena is virtually pain free because it does not require tumescent anesthesia to be administered along the length of the target vein.   Varithena requires a mere 1cc of local anesthetic.
  • Varithena treatment is optimal for patients who have tortuous veins that are not candidates for thermal ablation via catheter.
  • There is no downtime associated with the Varithena treatment.   Patients can ambulate immediately post procedure and require compression hose for only 3 days.
  • Drs. Rosenberg and McNeill were primary investigators on the Phase III FDA approved clinical study assessing efficacy of Varithena in treating varicose veins.
  • Varicose veins are caused by the failure of the unidirectional valves in the venous system that propels blood up the leg against the constant downward pressure of gravity. Elevated venous pressures lead to varicose veins, with resultant leg heaviness, aching, swelling and elevated risk of phlebitis and DVT.

 

More About Varicose Veins

  • Venous insufficiency causes stagnant flow of blood in the dilated leg veins which increases the risk of superficial thrombophlebitis. Detailed studies have shown that nearly 10% of patients with superficial phlebitis have associated DVT due to clot progression from the surface veins, through perforator veins, into the deep system.
  • The DVTs associated with varicose veins cause every bit as much morbidity and potential mortality as do other DVTs. Treatment is similar.
  • Varithena is new treatment that allows effective diminishing of the refluxing vein segments and restoration of normal venous flow. Not all patients will be suitable candidates for Varithena, but many will find this to be a very effective and durable treatment option.
  • CVL would advise physicians and other providers to be aware of the potential risk of even asymptomatic moderate to large varicose veins. Patients should be encouraged to seek evaluation and treatment to restore normal leg vascular health and avoid potential serious complications.